{"data":{"issuanceinfo":{"industrycode":"204005","industry":"醫療保健","ipoprice":{"ceiling":"9.600","floor":"7.600"},"ipodate":{"start":"2019-10-31 00:00:00","end":"2019-11-05 00:00:00"},"minimumcapital":"2909.02","subscribed":"12.87","marketcap":"76.47億","H_marketcap":"--","pe":"--","codesrate":"100.00","link":"https://staticpdf.iqdii.com/stockdata/notice/03681/2019/2019103100066_c.pdf","ipopricing":"7.600","resultdate":"2019-11-11 00:00:00","enddate":"2019-11-05 00:00:00","listeddate":"2019-11-12 00:00:00","issuenumber":"18212.94萬","issuenumberhK":"1821.30萬","issuenumberother":"16391.64萬","grayprice":"7.60","sponsors":"中國國際金融香港證券有限公司,東方融資(香港)有限公司","raisemoney":"128644.00萬","use":"1、約50.00%或643.22百萬港元將分配至研發及商業化在研藥物；\n2、約40.00%或514.58百萬港元將用于建設我們的蘇州生產基地，其主要用作我們核心產品SM03的商業化規模生產；\n3、約10.00%或128.64百萬港元將用于我們的營運資金、擴大內部能力及其他一般企業用途。","shares":300,"leadagent":"中國國際金融香港證券有限公司,東方證券(香港)有限公司,中國光大證券(香港)有限公司,國泰君安證券(香港)有限公司,招銀國際融資有限公司,海通國際證券有限公司,復星恒利證券有限公司,勝利證券有限公司","bookrunners":"中國國際金融香港證券有限公司,東方證券(香港)有限公司,中國光大證券(香港)有限公司,國泰君安證券(香港)有限公司,招銀國際融資有限公司,海通國際證券有限公司,復星恒利證券有限公司,勝利證券有限公司","coordinator":"中國國際金融香港證券有限公司,東方證券(香港)有限公司","firstDayOpen":"7.30","IsEiio":0,"Interestdays":6,"PENote":"按經審核的最近年度公司股東應占溢利和發行后總股本計算；發行價未確定時，按招股價中間價計算；發行價確定后，按招股定價計算。","OverAllotment":"有","StabilizingManager":"中國國際金融香港證券有限公司","code":"E03681","name":"中國抗體—Ｂ","fullname":"中國抗體制藥有限公司"},"institutioninfo":{"principaloffice":"香港皇后大道東183號合和中心54樓","registrars":"香港中央證券登記有限公司","registrarstel":"(852) 2862 8628 ","chairman":"梁瑞安","secretary":"黃佩彥","telephone":"(852) 3426 9833","substantialshareholders":"Apricot實體(21.16%),致譽投資集團有限公司(19.82%),Skytech Technology Limited(17.77%),海南海藥股份有限公司(15.11%)","principalactivities":"公司是專門研究、發展、制造及商業化免疫性疾病療法的香港生物制藥公司，主要研制以單克隆抗體為基礎的生物藥。","website":"http://www.sinomab.com/"},"managerinfo":[{"managername":"梁瑞安","post":"執行董事、董事會主席兼首席執行官","rankno":1},{"managername":"劉文溢","post":"非執行董事","rankno":2},{"managername":"陳海剛","post":"非執行董事","rankno":3}],"investorinfo":[{"institutionname":"云南白藥集團股份有限公司","shareholding":"51,599,400.0","percentage":28.33,"ReleaseDate":"2020-05-12 00:00:00","relatedparty":"云南省國資委","subsidiary":["云南白藥集團股份有限公司","云南省投資控股集團有限公司"],"InverstorType":"公司"},{"institutionname":"瑞捷軟件科技(香港)有限公司","shareholding":"10,319,700.0","percentage":5.67,"ReleaseDate":"2020-05-12 00:00:00","relatedparty":"深圳市高特佳投資集團有限公司","subsidiary":["Gaotejia Investment Management Co., Ltd","深圳市高特佳睿寶投資合伙企業(有限合伙)","瑞捷軟件科技(香港)有限公司"],"InverstorType":"公司"}],"TotalShareholdingPercentage":34},"result":1,"Version":"4.5.190802.46408","ElapsedMilliseconds":10}